|
US2020299779A1
|
|
Methods for detecting head and neck cancer
|
|
WO2017129716A1
|
|
Methods for detecting cpg methylation of tumor-derived dna in blood samples
|
|
EP3234184A1
|
|
Methods for detecting cpg methylation and for diagnosing cancer
|
|
EA034232B1
|
|
Methods and nucleic acids for determining the prognosis of a cancer subject
|
|
US2011104695A1
|
|
Methods of predicting therapeutic efficacy of cancer therapy
|
|
EP2309005A1
|
|
Methods for preservation of genomic DNA sequence complexity
|
|
WO2010149782A1
|
|
Methods and nucleic acids for analysis of bladder cell proliferative disorders
|
|
EP2660337A2
|
|
Method of prediciting the prognosis of a breast cancer therapy based on gene methylation analysis
|
|
EP2255017A1
|
|
A method for optimizing and validating an assay for determining the presence or absence of a medical condition
|
|
EP2071035A1
|
|
Facilitator and method for amplification
|
|
US2009203011A1
|
|
Methods and nucleic acids for analyses of cell proliferative disorders
|
|
CA2708163A1
|
|
Methods and nucleic acids for analyses of cell proliferative disorders
|
|
EP2189538A1
|
|
An analysis molecule and method for the analysis of a nucleotide position in a nucleic acid
|
|
EP2261366A1
|
|
Methods and nucleic acids for the analysis of CpG methylation associated with the development of prostate cell proliferative disorders
|
|
EP2152902A2
|
|
Method for methylation analysis
|
|
EP2258871A1
|
|
Methods and nucleic acids for analyses of cell proliferative disorders
|
|
EP3184649A1
|
|
Methods and nucleic acids for the analysis of gene expression associated with the development of prostate cell proliferative disorders
|
|
WO2008053357A2
|
|
Methods, systems and computer program products for determining treatment response biomarkers
|
|
WO2008047234A1
|
|
A molecule for providing a standard for the quantitative analysis of the methylation status of a nucleic acid
|
|
EP1914320A2
|
|
A method for detection of one or more CpG positions
|
